Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player
FARMINGTON, Conn., Jan. 24, 2013 /PRNewswire-iReach/ -- The companion diagnostics market has experienced significant growth in recent years and has become one of the most promising areas within the IVD market. A myriad of pharmaceutical and diagnostic companies are now entering the highly attractive market of companion diagnostics, many of them entering into collaborations for developing a combination product. The explosive M&A trend in the companion diagnostics market is expected to continue as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialization of the test once the drug is approved. However, it takes smart timing, the right technology and strategic relationships for companies to become a major companion diagnostic player.
In the last few years, most pharmaceutical companies have adopted new projects and strategies to develop companion diagnostic products. It seems most of these companies have begun to shift away from the blockbuster business model and realized that in order to be more effective, and save money, new drugs will have to be more personalized. Oncology remains the dominant field in the market; however, many of the leading companies are now reported to be working to develop companion diagnostics in other therapeutic areas including neurological, autoimmune, inflammatory and cardiovascular diseases
Technological advancements in the field, including the discovery of new biomarkers and the development of new molecular tests, has helped propel the companion diagnostics market which is clearly evidenced by the vast number of drugs in development that have an associated biomarker program. The market will be driven by the increasing development and use of biomarkers as well as the progressive decrease in costs of sequencing technologies. Biomarkers are now being employed at early stages of drug discovery and development, with many being increasingly developed into companion diagnostic tests.
Medical Device Leader Series - Top Companion Diagnostic Companies 2013-2023
The future of companion diagnostics appears promising and has significant potential for growth owing to the increasing demand for safer and more effective therapies. Furthermore, the global companion diagnostics market will benefit from a positive reimbursement outlook in key regional markets, primarily due to the cost-effective nature of the tests.
Leading companion diagnostic companies profiled in the report include: Abbott Laboratories, Inc., Myriad Genetics, Genomic Health, Johnson and Johnson, LabCorp, Life Technologies, QIAGEN, Roche, Dako (Agilent Technologies, bioMerieux, Siemens, and MDx Health.
Highlights from the report include: the growing number of companies entering the companion diagnostics market; Roche as a one stop shop for companion diagnostics; commercial market drivers; and emerging technologies that will help drive the companion diagnostics market forward.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/kt253510-medical-device-leader-series-top-needle-free.html
The Complete Guide to Companion Diagnostics: Market Environment Products and Companies
While personalized medicine is not new it is only relatively recently that diagnostics companies and pharma have converged to explore and exploit its potential benefits. By using companion diagnostics, companies can identify those patients who will benefit most from, or suffer fewer side effects from targeted therapies, and thereby present a more compelling approval and prescribing case to regulators and clinicians.
But here is the trade off. Companion diagnostics will ensure closer scrutiny of efficacy and cost benefit by regulators, users and health payers but also will end any revenue generating speculative prescribing.
Companion diagnostics are here to stay. It is unthinkable that, in time, biologic drugs will be approved without them. This compelling market study provides a complete appraisal of the competitive, regulatory and product issues shaping companion diagnostics.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/es256532-complete-guide-companion-diagnostics-market.html
Global Cancer Biomarkers Market 2012-2016
The global cancer biomarkers market is forecast to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Cancer Biomarkers market has also been witnessing the trend of the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.
The key vendors dominating the global cancer biomarkers market space are Abbott Laboratories, Affymetrix, Inc., Agilent Technologies Inc., Gen-Probe Inc., Hologic, Inc., and Roche Diagnostics Corp.
Additional vendors mentioned in the report include: Agendia BV, Ambrilia Biopharma, Astellas Pharma US Inc., Morphotek, Inc., Gen-Probe, Inc., Veridex LLC, Morphotek, Inc., Immunomedics, Inc., Clarient, Inc.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/infi260034-global-cancer-biomarkers-market.html
Competitive Intelligence: Analyses of 100 Major and Emerging Suppliers of Immunodiagnositcs, Microbiology, Cancer Diagnostic, Molecular Diagnostic, Hematology, Coagulation And Blood Banking Instruments and Reagents
This report provides analyses of 100 major and emerging suppliers of immunodiagnositcs, microbiology, cancer diagnostic, molecular diagnostic, hematology, coagulation and blood banking instruments and reagents. The report presents strategic profiles of 100 major and emerging suppliers of diagnostic products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/vpg252248-competitive-analyses-100-major-emerging-suppliers.html
For more market research highlights, technical research news and industry updates, please visit http://www.giiresearch.com/press/
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.